TITLE

US Food and Drug Administration Approval of Ciprofloxacin Hydrochloride for Management of Postexposure Inhalational Anthrax

AUTHOR(S)
Meyerhoff, Andrea; Albrecht, Renata; Meyer, Joette M.; Dionne, Peter; Higgins, Karen; Murphy, Dianne
PUB. DATE
August 2004
SOURCE
Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p303
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax. This was the first antimicrobial drug approved by the FDA for use in treating an infection due to a biological agent used intentionally. The terrorist attacks of 2001 involving anthrax underscore the imperative that safe and effective drugs to manage such infections be readily available in the United States. The approval of ciprofloxacin hydrochloride, which was made on the basis of a surrogate human marker of efficacy, made extensive use of data from an animal model of disease. This represents a new direction in the development of efficacy data in support of drug approval and facilitates the availability of those drugs for which there is an urgent need. This article presents the scientific data and regulatory mechanism that supported the approval of ciprofloxacin hydrochloride for management of postexposure of inhalational anthrax.
ACCESSION #
13919957

 

Related Articles

  • Gatifloxacin. Perry, C.M.; Barman Balfour, J.A.; Lamb, H.M. // Drugs;Oct1999, Vol. 58 Issue 4, p683 

    â–´ Gatifloxacin is a novel extended-spectrum fluoroquinolone with improved Gram-positive and anaerobe coverage compared with older agents such as ciprofloxacin. It has good activity (but is slightly less active than ciprofloxacin) against Enterobacteriaceae. â–´ Gatifloxacin is...

  • FDA Briefs.  // Ophthalmology Times;3/15/2005, Vol. 30 Issue 6, p8 

    The article presents information on the grant of an approval by FDA to HiTech Pharmacal Co.'s Abbreviated New Drug Application for ciprofloxacin ophthalmic solution USP, 0.3%. This is the generic equivalent of Alcon Laboratories Inc.'s Ciloxan Ophthalmic Solution, 0.3%, which is indicated for...

  • Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria. Fantin, Bruno; Duval, Xavier; Massias, Laurent; Alavoine, Loubna; Chau, Françoise; Retout, Sylvie; Andremont, Antoine; Mentré, France // Journal of Infectious Diseases;8/1/2009, Vol. 200 Issue 3, p390 

    Background. Although optimization of the fluoroquinolone dosage increases the efficacy of this class of drugs against bacterial infections, its impact on the emergence of resistance in commensal bacteria is unknown. Methods. Six different 14-day dosages of oral ciprofloxacin were randomly...

  • Clinical Significance of Roseomonas Species Isolated from Catheter and Blood Samples: Analysis of 36 Cases in Patients with Cancer. Do, Indra; Rolston, Kenneth V. I.; Han, Xiang V. // Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p1579 

    This report analyzes 36 cases of bacteremia or catheter-related infection caused by Roseomonas species, a group of pink, slimy, waterborne, gram-negative coccobadihi. The causative species included the newly described Roseomonas mucosa (22 cases [61%]) and Roseomonas gilardii subspecies rosen (8...

  • The costs of Cipro-mania. Cosh, Colby // Report / Newsmagazine (Alberta Edition);11/5/2001, Vol. 28 Issue 21, p4 

    Reports on the demand for the anti-anthrax antibiotic Cipro in the United States and Canada. Potential adverse physical effects of the drug; How mass use of Cipro may strengthen the resistance of many bacteria.

  • The costs of Cipro-mania. Cosh, Colby // Report / Newsmagazine (BC Edition);11/5/2001, Vol. 28 Issue 21, p4 

    Reports on the demand for the anti-anthrax antibiotic Cipro in the United States and Canada. Potential adverse physical effects of the drug; How mass use of Cipro may strengthen the resistance of many bacteria.

  • The costs of Cipro-mania. Cosh, Colby // Report / Newsmagazine (National Edition);11/5/2001, Vol. 28 Issue 21, p4 

    Reports on the demand for the anti-anthrax antibiotic Cipro in the United States and Canada. Potential adverse physical effects of the drug; How mass use of Cipro may strengthen the resistance of many bacteria.

  • Nanotech could be key to new anthrax detection test. PEDERSEN, AMANDA // Medical Device Daily;3/23/2009, Vol. 13 Issue 54, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has completed a proof-of-concept study of a test designed to detect the presence of even the smallest amount of the anthrax toxin. Study author Indira Hewlett said the FDA findings could form the basis of a test that allows...

  • FDA Targets Poultry Drugs to Curb Antibiotic Resistance.  // Environmental Nutrition;Jan2001, Vol. 24 Issue 1, p3 

    Reports on the decision of the United States Food and Drug Administration to remove two fluoroquinolone product used as poultry antibiotics because they are a threat to human health.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics